Device Trial Radar · NCT07943143
Histotripsy for Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
Oct 30, 2028
Study completion Oct 30, 2029
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gleneagles Hospital
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
Conditions
- Localised or Metastatic Renal Cell Carcinoma
Interventions
HistoSonics® Edison System (US)Device
Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess efficacyTime frame: 90 days post procedure
- To assess treatment safetyTime frame: At 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gleneagles Hospital Hong Kong
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.